Replies to post #14347 on GTC Biotherapeutics (fka GTCB)

[read_this_n0w]

there is no capital crunch on big pharma, drug proceeds will remain high and profit margins decent to great... they do lack new makets, but medicine is a very healthy and very cash rish industry

[DewDiligence]

Re: FoB deals

>The group of MAB on which GTC is focusing come only off patent over the next 6 to 8 years. So any potential partner is not in a hurry…<

How long do you think it takes to run a development program and obtain regulatory approval?

>… especially not in these days of capital crunch<

At RTN said, Big Pharma does not have any shortage of capital. To the contrary, they are more loaded with cash than ever.

If there’s an impediment to GTC’s inking an FoB deal, it’s not a shortage of capital but rather the uncertainty regarding what kind of FoB legislation Congress will enact and when they enact it. Regards, Dew